​
PLEASANTON, Calif.— The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal second quarter ended April 30, 2014.

Revenue increased 7 percent year-over-year to $412.3 million, up 9 percent in constant currency and excluding the divestiture of Aime, which was CVI’s rigid gas permeable contact lens and solutions business in Japan, sold effective Oct. 31, 2013. Net income for The Cooper Cos was $79.1 million for the quarter.

CooperVision (CVI) vision reported revenue up 7 percent to $331.1 million, up 9 percent in constant currency and excluding the divestiture of Aime. The CooperSurgical (CSI) revenue increased 9 percent to $81.2 million for the period.

Commenting on the results, Robert S. Weiss, Cooper's president and CEO, said, "I am proud to report another strong quarter for the company. We continued gaining market share within CVI driven by our silicone hydrogel family of products, especially Biofinity and MyDay. CSI also posted solid revenue growth driven by its fertility business. As we move into the second half of the year, we remain positive on our markets and our ability to continue taking market share."

Sales in the Americas, for the second quarter period, for contact lenses were $142.1 million, comprising 43 percent of CVI total revenue. Silicone hydrogel sales comprised 49 percent of CVI total revenue, or $161 million for the period, experiencing a 21 percent increase while CVI’s Proclear sales were $83.6 million or 25 percent of CVI revenues, an 8 percent increase over the prior year period.